What is the status on the combination trial of VX-770 and VX-809?
In the fall of 2010, Vertex launched a clinical trial to evaluate multiple combinations of VX-770 and VX-809. Vertex expects to have interim data from the combination trial in the first half of 2011. The trial will test the safety and tolerability of the two drugs in individuals with two copies of the most common CF mutation, Delta F508. Research in the laboratory suggests that using more than one drug may work better on the defective CFTR protein than using one drug alone.
